Join

Compare · ELV vs VCYT

ELV vs VCYT

Side-by-side comparison of Elevance Health Inc. (ELV) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ELV and VCYT operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ELV is the larger of the two at $90.24B, about 23.2x VCYT ($3.89B).
  • VCYT has been more active in the news (17 items in the past 4 weeks vs 3 for ELV).
  • Both have 23 recent analyst ratings on file.
MetricELVVCYT
Company
Elevance Health Inc.
Veracyte Inc.
Price
$419.74+0.98%
$48.34-0.83%
Market cap
$90.24B
$3.89B
1M return
-
-
1Y return
-
-
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2013
News (4w)
3
17
Recent ratings
23
23
ELV

Elevance Health Inc.

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

VCYT

Veracyte Inc.

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Latest ELV

Latest VCYT